Michelle Kim Leff
About Michelle Kim Leff
Michelle Kim Leff serves as the Chief of Staff at the National Institutes of Health and has extensive experience in child psychiatry and technology development. She holds a Doctor of Medicine degree from New York University and an MBA from The Wharton School.
Current Role at National Institutes of Health
Michelle Kim Leff serves as Chief of Staff at the National Institutes of Health (NIH) since 2011. In this role, she oversees various administrative functions and supports the strategic direction of the organization. Her experience in leadership positions within NIH contributes to her effectiveness in managing operations and facilitating communication across departments.
Previous Experience at National Institutes of Health
Prior to her current position, Michelle Kim Leff worked as Deputy Clinical Director at the National Institutes of Health from 2002 to 2011. During her tenure, she played a significant role in clinical operations and contributed to the development of research initiatives within the organization.
Education and Medical Training
Michelle Kim Leff earned her Doctor of Medicine degree from New York University School of Medicine, completing her studies from 1983 to 1987. She also holds a Bachelor of Arts in Biology from Harvard University, which she obtained from 1979 to 1983. Additionally, she received a Master of Business Administration from The Wharton School, studying from 2005 to 2007.
Professional Background in Child Psychiatry
Michelle Kim Leff has extensive experience in child psychiatry. She served as Medical Director of Child Psychiatry at Johns Hopkins University from 1996 to 2002. Earlier in her career, she worked as a Child and Adolescent Psychiatrist in the U.S. Army from 1987 to 1996, providing mental health services to young patients.
Current Role at National Institute on Drug Abuse
Since 2012, Michelle Kim Leff has held the position of Technology Development Coordinator at the National Institute on Drug Abuse (NIDA). In this capacity, she focuses on advancing technological initiatives that support research and treatment related to drug abuse and addiction.